Sales focus on generic drugs and products eligible for the premium for promoting new drug creation
First written in FY2017-Q1. 10 of 11 entries say "Restated". Latest entry: FY2020-Q3.
4 other companies' latest entry also says "Restated".
- FY2020-Q3RestatedAnnual report
「Although sales of prescription pharmaceuticals and other products were affected by the National Health Insurance drug price revision implemented on 1 October 2019, sales remained firm due to growth in new drugs, including anticancer drugs.」
The company continues to focus on sales of new drugs, including anticancer drugs, amid the impact of the drug price revision. - FY2020-Q2RestatedAnnual report
「Although sales of prescription pharmaceuticals and other products were affected by customers holding back purchases ahead of the National Health Insurance drug price revision implemented on 1 October 2019, sales remained firm due to growth in new drugs, including anticancer drugs, and front-loaded demand associated with the increase in the consumption tax rate.」
The company continues to focus on new drugs, including anticancer drugs, amid an environment of reduced purchasing ahead of the drug price revision and front-loaded demand ahead of the consumption tax increase. - FY2019-Q3RestatedAnnual report
「Sales of prescription drugs and related products remained at the previous year's level, despite the impact of the drug price cut implemented on 1 April 2018 and efforts to promote the use of generic drugs, as sales of new drugs such as anticancer drugs and hepatitis C treatments increased.」
The company continues to focus on sales of new drugs such as anticancer drugs and hepatitis C treatments amid drug price cuts and efforts to promote the use of generic drugs. - FY2019-Q2RestatedAnnual report
「Sales of prescription drugs and related products remained at the previous year's level, despite the impact of the drug price cut implemented on 1 April 2018 and efforts to promote the use of generic drugs, as sales of new drugs such as anticancer drugs and hepatitis C treatments increased.」
The company continues to focus on sales of new drugs such as anticancer drugs and hepatitis C treatments amid drug price cuts and efforts to promote the use of generic drugs. - FY2019-Q1RestatedAnnual report
「Sales of prescription pharmaceuticals and related products remained firm despite the impact of the drug price reduction implemented on 1 April 2018 and the promotion of generic drug use, supported by contributions from new drugs such as anticancer drugs and hepatitis C treatments.」
The Company continues to focus on new drugs, including anticancer drugs and hepatitis C treatments, amid drug price reductions and the promotion of generic drug use. - FY2018RestatedAnnual report
「Sales of prescription pharmaceuticals and related products remained firm amid a flat market affected by the promotion of generic drug use and declining demand for hepatitis C treatments.」
The Company continues sales-side initiatives, including the promotion of generic drug use, and sales remained firm while the market was flat. - FY2018-Q3RestatedAnnual report
「Sales of prescription pharmaceuticals remained firm amid a flat market affected by the promotion of generic drug use and declining demand for hepatitis C treatments.」
The Company continues sales-side initiatives, including the promotion of generic drug use. Sales remained firm in a flat market environment. - FY2018-Q2RestatedAnnual report
「Sales of prescription pharmaceuticals and related products remained at approximately the same level as the same period of the previous fiscal year, amid negative market growth caused by the promotion of generic drug use and declining demand for hepatitis C treatments.」
The Company continues to promote generic drug use as a sales-side initiative, but the market posted negative growth due in part to declining demand for hepatitis C treatments. - FY2017-Q3RestatedAnnual report
「Although the company actively pursued sales of generic drugs, for which demand is expanding, and new drugs, the market contracted because of the National Health Insurance drug price reduction implemented in April 2016 and the peaking of demand for hepatitis C treatments, resulting in difficult conditions.」
In response to drug price reductions, the Company continues to focus on selling generic drugs and new drugs, for which demand is expanding. - FY2017-Q2RestatedAnnual report
「Sales of prescription pharmaceuticals remained difficult, despite efforts focused on generic drugs, for which demand is expanding, and new drugs, due to the impact of the National Health Insurance drug price reduction implemented in April 2016 and declining sales as demand for hepatitis C treatments, which had expanded in the previous year, reached maturity.」
The Company continues to focus on sales of generic drugs and new drugs, but drug price reductions and the end of the cycle of demand for hepatitis C treatments are affecting the sales environment. - FY2017-Q1First statedAnnual report
「Sales remained at approximately the same level as the same period of the previous fiscal year, partly because the Company focused on selling generic drugs, for which demand is expanding, and products eligible for the new drug creation premium.」
As a sales initiative to address the impact of drug price reductions, the Company reported a focus on selling generic drugs, for which demand is expanding, and products eligible for the new drug creation premium.